Jan D Schmitto1, Yuriy Pya2, Daniel Zimpfer3, Thomas Krabatsch4, Jens Garbade5, Vivek Rao6, Michiel Morshuis7, Friedhelm Beyersdorf8, Silvana Marasco9, Poornima Sood10, Laura Damme10, Ivan Netuka11. 1. Hannover Medical School, Hannover, Germany. 2. National Research Cardiac Surgery Center, Astana, Kazakhstan. 3. University of Vienna, Vienna, Austria. 4. German Heart Center, Berlin, Germany. 5. Heart Center Leipzig, Leipzig, Germany. 6. Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada. 7. Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany. 8. University Heart Center Freiburg-Bad Krozingen, Medical Faculty, Albert Ludwigs-University, Freiburg, Germany. 9. The Alfred Hospital, Melbourne, Australia. 10. Abbott, Burlington, MA, USA. 11. Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Abstract
AIM: This study aimed to assess safety and outcomes of patients, 2 years after implantation with the HeartMate 3 Left Ventricular Assist System. METHODS AND RESULTS: This study included 50 adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure with an ejection fraction ≤25% and a cardiac index ≤2.2 L/min/m2 without inotropes, or inotrope-dependent with optimal medical management, or listed for heart transplant. The median duration of left ventricular assist device support was 694 days (range: 19-833 days). At baseline, cardiac index was 1.8 ±0.5 L/min/m2 , 58% of patients were receiving inotropes, and 92% were INTERMACS profiles 2-4. At 2 years, Kaplan-Meier survival was 74 ±6%, 5 (10%) patients were transplanted, and 32 patients (64%) remain with support. Adverse event rates include bleeding requiring surgery (16%), gastrointestinal bleeding (20%), driveline infection (24%), ischaemic stroke (16%), haemorrhagic stroke (8%), right heart failure (14%), and outflow graft thrombosis (2%). Notably, no haemolysis, pump thrombosis, or pump malfunction events occurred. At 2 years, 47% of patients remained in NYHA class I and 41% in NYHA class II (P <0.0001). From baseline to 2 years, the mean six-minute walk distance increased from 239 m to 347 m (P <0.0001), and the mean EQ-5D quality of life score improved from 48.2 to 70.6 (P < 0.0001). CONCLUSIONS: Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany. ClinicalTrials.gov: NCT02170363.
AIM: This study aimed to assess safety and outcomes of patients, 2 years after implantation with the HeartMate 3 Left Ventricular Assist System. METHODS AND RESULTS: This study included 50 adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure with an ejection fraction ≤25% and a cardiac index ≤2.2 L/min/m2 without inotropes, or inotrope-dependent with optimal medical management, or listed for heart transplant. The median duration of left ventricular assist device support was 694 days (range: 19-833 days). At baseline, cardiac index was 1.8 ±0.5 L/min/m2 , 58% of patients were receiving inotropes, and 92% were INTERMACS profiles 2-4. At 2 years, Kaplan-Meier survival was 74 ±6%, 5 (10%) patients were transplanted, and 32 patients (64%) remain with support. Adverse event rates include bleeding requiring surgery (16%), gastrointestinal bleeding (20%), driveline infection (24%), ischaemic stroke (16%), haemorrhagic stroke (8%), right heart failure (14%), and outflow graft thrombosis (2%). Notably, no haemolysis, pump thrombosis, or pump malfunction events occurred. At 2 years, 47% of patients remained in NYHA class I and 41% in NYHA class II (P <0.0001). From baseline to 2 years, the mean six-minute walk distance increased from 239 m to 347 m (P <0.0001), and the mean EQ-5D quality of life score improved from 48.2 to 70.6 (P < 0.0001). CONCLUSIONS: Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany. ClinicalTrials.gov: NCT02170363.
Authors: Nicholas McNamara; Harry Narroway; Michael Williams; John Brookes; James Farag; David Cistulli; Paul Bannon; Silvana Marasco; Evgenij Potapov; Antonio Loforte Journal: Ann Cardiothorac Surg Date: 2021-03
Authors: Silvia Mariani; Tong Li; Karl Bounader; Dietmar Boethig; Alexandra Schöde; Jasmin S Hanke; Jana Michaelis; L Christian Napp; Dominik Berliner; Guenes Dogan; Roberto Lorusso; Axel Haverich; Jan D Schmitto Journal: Ann Cardiothorac Surg Date: 2021-03
Authors: Jan M Sommerlath Sohns; Hannah Kröhn; Alexandra Schöde; Thorsten Derlin; Axel Haverich; Jan D Schmitto; Frank M Bengel Journal: J Nucl Med Date: 2019-12-05 Impact factor: 11.082
Authors: Claudius Mahr; Duc Thinh Pham; Nahush A Mokadam; Scott C Silvestry; Jennifer Cowger; Michael S Kiernan; David A D'alessandro; Erin E Coglianese; Muhammad Faraz Masood; Robert L Kormos; Mary V Jacoski; Jeffrey J Teuteberg Journal: ASAIO J Date: 2019 Mar/Apr Impact factor: 2.872
Authors: Mojgan Ghodrati; Thananya Khienwad; Alexander Maurer; Francesco Moscato; Francesco Zonta; Heinrich Schima; Philipp Aigner Journal: Int J Artif Organs Date: 2020-02-05 Impact factor: 1.595